Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2024

Open Access 01-12-2024 | Solifenacin | Research

Efficacy and safety of solifenacin combined with biofeedback in children with overactive bladder

Authors: Yan Hu, Hui Zhang

Published in: BMC Urology | Issue 1/2024

Login to get access

Abstract

Background

Overactive bladder is a common chronic urological disorder in children, liable to impact normal social activities, disrupt sleep and even impair self-esteem. We aimed to evaluate the efficacy and safety of solifenacin combined with biofeedback for paediatric overactive bladder.

Method

Forty-five children with overactive bladder were enrolled and divided into three groups: 15 patients in Group A were treated with solifenacin, 15 cases in Group B with biofeedback, and the other 15 patients in Group C with the combination of solifenacin plus biofeedback. Each group was subdivided into the non-urge incontinence (non-UI) and urge incontinence (UI) groups. The remission rates were compared among the three groups at 2, 4, 8 and 12 weeks from the beginning of treatment. The side effects of solifenacin were recorded and followed up.

Result

After 2 weeks since initial treatment, the complete response rates were 33.3% (5/15), 20.0% (3/15), and 53.3% (8/15) in the three groups. At 4 weeks, the complete remission rates were 46.7% (7/15), 33.3% (5/15), and 60.0% (9/15) respectively. Moreover, the complete remission rates of the UI groups were higher than the non-UI groups (p < 0.05). At 8 weeks, the complete response rates were 53.3% (8/15), 40.0% (6/15), and 67.7% (10/15). At 12 weeks, the complete response rates were 67.8% (10/15), 60.0% (9/15), and 86.7% (13/15). The complete response rates were higher and urodynamic parameters were improved obviously in group C than the other two groups (p < 0.05) during the follow-ups. The median voiding frequency decreased and median functional bladder capacity increased obviously in Group C after 4 weeks (p < 0.05). Dry mouth was observed in 2 patients (4.4%). 2 patients experienced constipation (4.4%), and neither case was severe. The symptoms of these four patients had relieved by reducing the dose of solifenacin.

Conclusion

Solifenacin combined with biofeedback had good efficacy and compliance for children experiencing overactive bladder. It took only 2 weeks to achieve the complete response rate over 50%, especially for the improvement of UI symptoms.
Literature
1.
2.
Zhu B, Liu Y, Wang H, Duan F, Mi L, Liang Y. Clinical guidelines of UTIs in children: quality appraisal with AGREE II and recommendations analysis. BMJ Open. 2022;12(4):e057736.CrossRefPubMedPubMedCentral
3.
Digesu GA, Khullar V, Cardozo L, Salvatore S. Overactive bladder symptoms: Do we need urodynamics? Neurourol Urodyn. 2003;22:105–8.CrossRefPubMed
4.
Flisser AJ, Walmsley K, Blaivas JG. Urodynamic classification of patients with symptoms of overactive bladder. J Urol. 2003;169:529–34.CrossRefPubMed
5.
Austin PF, Bauer SB, Bower W, Chase J, Franco I, Hoebeke P, et al. The standardization of terminology of lower urinary tract function in children and adolescents: Update report from the standardization committee of the International Children’s Continence Society. Neurourol Urodyn. 2016;35(4):471–81.CrossRefPubMed
6.
Chung JM, Lee SD, Kang DI, Kwon DD, Kim KS, Kim SY, et al. Prevalence and associated factors of overactive bladder in Korean children 5–13 years old: a nationwide multicenter study. Urology. 2009;73:63–7.CrossRefPubMed
7.
Goode PS, Burgio KL, Locher JL, Umlauf MG, Lloyd LK, Roth DL. Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women. J Am Geriatr Soc. 2002;50:808–16.CrossRefPubMed
8.
Burgio KL, Goode PS, Locher JL, Umlauf MG, Roth DL, Richter HE, et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: A randomized controlled trial. JAMA. 2002;288:2293–9.CrossRefPubMed
9.
Tugtepe H, Thomas DT, Ergun R, Abdullayev T, Kastarli C, Kaynak A, et al. Comparison of Biofeedback Therapy in Children with Treatment-refractory Dysfunctional Voiding and Overactive Bladder. Urol. 2015;85(4):900–4.CrossRefPubMed
10.
Hodges SJ, Atala A. A randomized placebo-controlled study of the efficacy of antimuscarinics in the treatment of pediatric overactive bladder and incontinence. Curr Urol Rep. 2009;10:6–7.CrossRefPubMed
11.
Newgreen D, Bosman B, Hollestein-Havelaar A, Dahler E, Besuyen R, Sawyer W, et al. Solifenacin in children and adolescents with overactive bladder: results of a phase 3 randomised clinical trial. Eur Urol. 2017;71:483–90.CrossRefPubMed
12.
Hoebeke P, De Pooter J, De Caestecker K, Raes A, Dehoorne J, Van Laecke E, et al. Solifenacin for therapy resistant overactive bladder. J Urol. 2009;182(Suppl 4):2040–4.CrossRefPubMed
13.
Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc. 2000;48:370–4.CrossRefPubMed
14.
Kajiwara M, Inoue K, Kato M, Usui A, Kurihara M, Usui T. Nocturnal enuresis and overactive bladder in children: an epidemiological study. Int J Urol. 2006;13:36–41.CrossRefPubMed
15.
16.
van Gool JD, de Jong TPVM, Winkler-Seinstra P, Tamminen-Möbius T, Lax H, Hirche H, et al. Multi-center randomized controlled trial of cognitive treatment, placebo, oxybutynin, bladder training, and pelvic floor training in children with functional urinary incontinence. Neurourol Urodyn. 2014;33:482–7.CrossRefPubMed
17.
Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004;93:303–10.CrossRefPubMed
18.
Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol. 2002;41:588–95.CrossRefPubMed
19.
Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003;78:687–95.CrossRefPubMed
20.
21.
Sussman DO. Overactive bladder: treatment options in primary care medicine. J Am Osteopath Assoc. 2007;107(9):379–85.PubMed
22.
Chapple CR, Fianu-Jonsson A, Indig M, Khullar V, Rosa J, Scarpa RM, et al. Treatment outcomes in the STAR study: A subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol. 2007;52:1195–203.CrossRefPubMed
23.
Lee SD, Chung JM, Kang DI, Ryu DS, Cho WY, Park S. Efficacy and tolerability of solifenacin 5 mg fixed dose in Korean children with newly diagnosed idiopathic overactive bladde: a multicenter prospective study. J Korean Med Sci. 2017;32(2):329–34.CrossRefPubMed
24.
Chancellor M, Boone T. Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther. 2012;18(2):167–74.CrossRefPubMed
25.
Franco I, Hoebeke P, Baka-Ostrowska M, Bolong D, Davies LN, Dahler E, et al. Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies. J Pediatr Urol. 2020;16(2):180.e1-180.e8.CrossRefPubMed
26.
Yamaguchi O. Long-term safety and efficacy of solifenacin succinate in patients with overactive bladder. Jpn Pharmacol Ther. 2006;34:S69-86.
Metadata
Title
Efficacy and safety of solifenacin combined with biofeedback in children with overactive bladder
Authors
Yan Hu
Hui Zhang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2024
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-024-01486-9

Other articles of this Issue 1/2024

BMC Urology 1/2024 Go to the issue

Research

The effects of different positions on lower extremity hemodynamics during robot-assisted laparoscopic radical prostatectomy for prostate cancer

Research

CT findings and clinical characteristics in distinguishing renal urothelial carcinoma mimicking renal cell carcinoma from clear cell renal cell carcinoma

Research

Survival and clinicopathological significance of B7-H3 in bladder cancer: a systematic review and meta-analysis

Research

Percutaneous nephrolithotomy guided by 5G-powered robot-assisted teleultrasound diagnosis system: first clinical experience with a novel tele-assistance approach (IDEAL stage 1)

Research

The prevalence of probable overactive bladder and associated risk factors among medical students in Jordan: a cross-sectional study

Research

Is switching intravesical chemotherapeutic agents beneficial in short-term recurrent high-risk non-muscle-invasive bladder tumors? A 5-year retrospective study